Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Chronic Kidney Disease Drugs Market – Insights
Chronic kidney disease (CKD) involves gradual loss of functioning of kidneys. The normal function of kidneys are to filter out and excrete wastes, and excess fluids from the blood are excreted through urine. However, when an individual is suffering from chronic kidney disease, kidneys cannot perform their natural function and wastes, fluids, and electrolytes build up in the body in excess amounts. Signs and symptoms of chronic kidney disease are not apparent until kidney function becomes significantly impaired. The supportive treatment of chronic kidney disease includes delaying the disease progression and kidney damage. Diseases and conditions such as type 1 or type 2 diabetes, high blood pressure, polycystic kidney disease, and recurrent kidney infection leads to chronic kidney disease. Factors that increase risk of chronic kidney disease include diabetes, high blood pressure, smoking, obesity, and others. Management of the disease involves managing the co-morbidities such as blood pressure, diabetes medications, medications to lower cholesterol levels, and anemia treatment. Kidney dialysis and kidney transplant may become a necessity, as the condition becomes worse. There is no direct medication available for the treatment of chronic kidney disease. Chronic kidney diseases may trigger other healthcare issues such as cardiovascular diseases.
High prevalence of diseases leading to chronic kidney diseases are expected to foster growth of the chronic kidney disease drugs market
Diseases such as diabetes and high blood pressure increase the risk of chronic kidney diseases. According to Kidney Health Australia, 2010, the cost of treating all current and new cases of End Stage Kidney Disease (ESKD) will reach up to US$ 12 billion by 2020. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. are estimated to have chronic kidney disease in 2017. CDC states that around 96% of the people with kidney damage or hampered kidney function are not aware of having chronic kidney disease, which indicates the underlying market potential in chronic kidney disease drugs market. Moreover, according to CDC, high blood pressure and diabetes are leading causes of chronic kidney disease. Approximately 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. According to the American Diabetes Association (ADA), in 2015, 30.3 million people in the U.S. were suffering from diabetes. According to CDC, in 2014, around 118,000 people in the U.S. started the treatment for end stage renal disease and as more people become aware of this condition, the number of people for treatment will increase. These factors are expected to boost the market growth over the forecast period.
The global chronic kidney disease drugs market was valued at US$ 12,468.2 million in 2017 and is expected to witness a robust CAGR of 3.1% over the forecast period (2018 – 2026).
Figure 1. Global Chronic Kidney Disease Drugs Market Share, by Region, 2018
Source: Coherent Market Insights Analysis (2017)
Initiatives taken by government organizations and manufacturers to increase awareness of chronic kidney disease is expected to boost the market growth over the forecast period
Individual government organizations and manufacturers are working towards increasing the awareness of chronic kidney diseases. For instance, American Kidney Fund (AKF) launched comprehensive new kidney disease education portal in May 2018. The education portal called as ‘CKD Central’ will provide information and resources on chronic kidney disease (CKD). In March 2018, Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease. Moreover, CVS Health Corporation launched kidney disease initiative in April 2018. In March 2018, Fresenius Medical North America (FMCNA) made a contribution of US$ 40,000 to Kidney School, world’s largest education program for people with chronic kidney disease.
However, delay in the diagnosis of chronic kidney disease is expected to hinder growth of the chronic kidney disease drugs market over the forecast period.
Some major players operating in the chronic kidney disease drugs market include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.